How did SABS's revenue and expenses trend in Q4 2024?
5/8/2025 08:32am
Aime
SAB Biotherapeutics (SABS) reported a revenue of $1.32 million and operating expenses of $11.39 million in Q4 2024, resulting in a net loss of $11.07 million. The gross profit margin was 100%, indicating that the company's cost of goods sold was zero or negligible compared to its revenue1.
1/3
SABS Revenue By Business
Date
Business Composition
Revenue By Business
20240101-2024
Grant
1.32M
20240101-2024
Grant
1.21M
20240101-2024
Grant
1.21M
20240101-2024
Grant
944.58K
20240101-2024
Grant
944.58K
Name
SAB BiotherapeuticsSABS
SAB BiotherapeuticsSABS
SAB BiotherapeuticsSABS
SAB BiotherapeuticsSABS
SAB BiotherapeuticsSABS
View null result
Source:
1.
SABS Revenue by Business, Net Income, Operating Expenses, Gross Margin in Q4 2024
more
less
Explore
Screener
What are the best stocks to buy now?
Analysis
Aple Rating chart
Learn
Advanced technical indicators and how they are calculated and utilized